RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.
Saved in:
| Title: | RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar. |
|---|---|
| Authors: | Grobbee EJ; Department of Gastroenterology and Hepatology, Erasmus MC Medical Center, Rotterdam, The Netherlands., de Jong VD; Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Julius Clinical, Zeist, The Netherlands., Schrieks IC; Julius Clinical, Zeist, The Netherlands., Tushuizen ME; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands., Holleboom AG; Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands., Tardif JC; Montreal Heart Institute Coordinating Center, Université de Montréal, Montreal, Canada., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, United States of America., Schwartz GG; Division of Cardiology, VA Medical Center and University of Colorado School of Medicine, Denver, CO, United States of America., Castro Cabezas M; Julius Clinical, Zeist, The Netherlands.; Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.; Department of Endocrinology, Erasmus MC Medical Center, Rotterdam, The Netherlands., Grobbee DE; Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Julius Clinical, Zeist, The Netherlands. |
| Source: | PloS one [PLoS One] 2022 Nov 15; Vol. 17 (11), pp. e0277706. Date of Electronic Publication: 2022 Nov 15 (Print Publication: 2022). |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36378671 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Grobbee+EJ%22">Grobbee EJ</searchLink>; Department of Gastroenterology and Hepatology, Erasmus MC Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Jong+VD%22">de Jong VD</searchLink>; Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Julius Clinical, Zeist, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Schrieks+IC%22">Schrieks IC</searchLink>; Julius Clinical, Zeist, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Tushuizen+ME%22">Tushuizen ME</searchLink>; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Holleboom+AG%22">Holleboom AG</searchLink>; Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Tardif+JC%22">Tardif JC</searchLink>; Montreal Heart Institute Coordinating Center, Université de Montréal, Montreal, Canada.<br /><searchLink fieldCode="AU" term="%22Lincoff+AM%22">Lincoff AM</searchLink>; Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, United States of America.<br /><searchLink fieldCode="AU" term="%22Schwartz+GG%22">Schwartz GG</searchLink>; Division of Cardiology, VA Medical Center and University of Colorado School of Medicine, Denver, CO, United States of America.<br /><searchLink fieldCode="AU" term="%22Castro+Cabezas+M%22">Castro Cabezas M</searchLink>; Julius Clinical, Zeist, The Netherlands.; Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.; Department of Endocrinology, Erasmus MC Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Grobbee+DE%22">Grobbee DE</searchLink>; Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Julius Clinical, Zeist, The Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2022 Nov 15; Vol. 17 (11), pp. e0277706. <i>Date of Electronic Publication: </i>2022 Nov 15 (<i>Print Publication: </i>2022). – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36378671 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1371/journal.pone.0277706 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e0277706 Titles: – TitleFull: RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Grobbee EJ – PersonEntity: Name: NameFull: de Jong VD – PersonEntity: Name: NameFull: Schrieks IC – PersonEntity: Name: NameFull: Tushuizen ME – PersonEntity: Name: NameFull: Holleboom AG – PersonEntity: Name: NameFull: Tardif JC – PersonEntity: Name: NameFull: Lincoff AM – PersonEntity: Name: NameFull: Schwartz GG – PersonEntity: Name: NameFull: Castro Cabezas M – PersonEntity: Name: NameFull: Grobbee DE IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 11 Text: 2022 Nov 15 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1932-6203 Numbering: – Type: volume Value: 17 – Type: issue Value: 11 Titles: – TitleFull: PloS one Type: main |
| ResultId | 1 |
